4SC AGの将来のP / E
4SC AGの将来のP / Eは何ですか。
4SC AGの将来のP / Eは-2.94です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
XETRAのセクタHealth Careにおける将来のP / Eの企業と比べる4SC AG
4SC AGは何をしますか。
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
4SC AGと類似の将来のp / e
- BioCardiaの将来のP / Eは-3.04です。
- BioCardiaの将来のP / Eは-3.04です。
- BioCardiaの将来のP / Eは-3.04です。
- BioCardiaの将来のP / Eは-3.04です。
- Rewalk Robotics Ltdの将来のP / Eは-3.02です。
- Workhorse Incの将来のP / Eは-3.02です。
- 4SC AGの将来のP / Eは-2.94です。
- Altimmune Incの将来のP / Eは-2.93です。
- Codexisの将来のP / Eは-2.86です。
- Co-Diagnostics Incの将来のP / Eは-2.85です。
- Brookdale Senior Living Incの将来のP / Eは-2.83です。
- Ocugen Incの将来のP / Eは-2.77です。
- IMAC Incの将来のP / Eは-2.77です。